Pfizer Inc. said an appeals court ruled in its favor in a patent infringement case over the drug maker's anti-convulsant Neurontin. The dispute relates to Pfizer's allegation of patent infringement over forms of gabapentin, the active ingredient in Neurontin. Pfizer says the patent does not begin expiring until 2017. In 2004, however, generic manufacturer Teva Pharmaceutical Industries Ltd. began shipping gabapentin tablets, which it says is the generic equivalent of Pfizer's Neurontin.
September 24, 2007 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Pfizer Inc. said on Sept. 21 an appeals court ruled in its favor in a patent infringement case over the drug maker’s anti-convulsant Neurontin.
The dispute relates to Pfizer’s allegation of patent infringement over forms of gabapentin, the active ingredient in Neurontin.
Presented by BigVoodoo
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
Women, Influence & Power in Law Awards honors women lawyers who have made a remarkable difference in the legal profession.
WIPL is the original global forum facilitating women-to-women exchange on leadership and legal issues.
Associate attorney position at NJ Immigration Law firm: Leschak & Associates, LLC, based in Freehold, NJ, is looking for a full time ass...
Javerbaum Wurgaft, a large civil litigation firm with nine (9) offices, seeks: Plaintiff Personal Injury Attorney for Northern New Jersey of...
Exciting Career Opportunities at Nuzzo & Roberts! Nuzzo & Roberts, a leading mid-sized insurance defense firm based in Cheshire, CT...
